Piper Sandler analyst David Westenberg raised the firm’s price target on Exact Sciences (EXAS) to $80 from $70 and keeps an Overweight rating on the shares. The firm cites the company’s quarterly results for the price target change.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences notes expiration of HSR waiting period for Freenome license pact
- Exact Sciences backs FY25 revenue view $3.22B-$3.24B, consensus $3.23B
- Exact Sciences price target raised to $85 from $65 at Citi
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- Exact Sciences announces results from ALTUS study